# Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

> **NCT04787042** · PHASE1,PHASE2 · RECRUITING · sponsor: **Simcha IL-18, Inc.** · enrollment: 316 (estimated)

## Conditions studied

- Cancer
- Solid Tumor
- Melanoma
- Renal Cell Carcinoma
- Triple-negative Breast Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma
- MSI-High

## Interventions

- **BIOLOGICAL:** ST-067
- **BIOLOGICAL:** Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT04787042
- **Lead sponsor:** Simcha IL-18, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-06
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787042, "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04787042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*